Kaida BioPharma Launches New Social Media Presence
Company committed to offering hope to patients facing treatment-resistant gynecological cancers
Lead program, KAD101, aimed at treating ovarian cancer is rapidly progressing toward a Phase 1 study set for 2025
Kaida BioPharma, an innovative early-stage pharmaceutical company, has recently unveiled its new corporate social media channels. This effort is designed to enhance communication about its groundbreaking cancer treatments and keep the community updated on recent advancements. By reaching out to healthcare professionals, investors, patients, and advocates, Kaida aims to expand its network.
Ovarian cancer presents significant hurdles, with many patients encountering limited treatment options post-diagnosis. Craig Pierson, the Founder and Chairman of Kaida BioPharma, highlighted the urgent demand for effective therapies, emphasizing that almost 90% of patients are in search of better alternatives. He affirmed Kaida’s dedication not just to alleviate symptoms but also to address the root causes of ovarian cancer. The team encourages everyone to join conversations about the future of gynecologic cancer care through their social media platforms.
Exploring Kaida's Innovative Solutions
At the core of Kaida's initiative is its leading program, KAD101. This novel biologic therapy is designed to block the prolactin receptor, aiming to stop cancer cell growth signals and encourage autophagy, initially focusing on ovarian cancer. Early human clinical trials are promising, indicating that KAD101 is not only safe but has resulted in tumor shrinkage in every patient examined, supporting its further development.
The much-anticipated Phase 1 study for KAD101 is scheduled to kick off in 2025, a major step towards offering a proactive treatment option for those suffering from ovarian cancer. Additionally, the company is developing KAD102, an advanced therapy targeting uterine cancer. This comprehensive pipeline highlights Kaida's commitment to creating impactful cancer treatments.
About Kaida BioPharma
Founded on robust research, Kaida BioPharma is dedicated to developing therapies that tackle the specific challenges women face when dealing with gynecological cancers. Collaborating with esteemed experts such as Dr. John Langenheim from Thomas Jefferson University and Dr. Anil Sood at MD Anderson strengthens Kaida’s solid foundation. Research surrounding KAD101 has demonstrated promising potential in combatting these challenging cancers.
Kaida BioPharma’s mission is straightforward: to inspire hope in patients seeking effective treatments for their conditions. With a steadfast commitment to innovative therapy development, the company is eager to change the narrative around treatment-resistant gynecological cancers.
Connect with Kaida BioPharma
To enhance connections with patients and the healthcare community, Kaida BioPharma has established its presence on various social media platforms. This move aims to engage more profoundly with investors, partners, and patients, ensuring everyone stays informed about their progress and developments.
If you need more information about Kaida BioPharma, feel free to reach out to Jenene Thomas, the Chief Executive Officer. You can contact her at 833.475.8247 or via email.
Frequently Asked Questions
What is Kaida BioPharma?
Kaida BioPharma is an early-stage pharmaceutical company focused on creating innovative treatments for ovarian cancer and other gynecological cancers.
What is KAD101?
KAD101 is a novel biologic therapy intended to block signals that promote cancer cell growth, specifically targeting ovarian cancer.
When is the Phase 1 study for KAD101 expected to commence?
The Phase 1 study for KAD101 is set to begin in 2025.
How has KAD101 performed in clinical studies?
Initial human clinical studies have demonstrated that KAD101 resulted in tumor reductions for all patients, alongside a favorable safety profile.
How can I find more information about Kaida BioPharma?
You can learn more by following Kaida BioPharma on their social media channels and visiting their official website.
